Conformational Restriction of Designer Drugs Reveals Subtype-Selective and Biased CB₂ Agonists with Neuroprotective...

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• Cannabinoid receptor 2 (CB2R) agonists offer therapeutic potential for neurodegenerative diseases.
• Existing CB2R ligands often lack selectivity, exhibiting off-target effects, including CB1R-mediated psychoactivity.
• Developing selective CB2R agonists with neuroprotective properties is crucial.

Purpose of the Study:

• To design, synthesize, and characterize novel, structurally simple, selective CB2R agonists.
• To achieve functional bias toward specific signaling pathways (β-arrestin, MAPK, G-protein).
• To evaluate anti-inflammatory and neuroprotective potential, ensuring no CB1R binding.

Main Methods:

• Conformational restriction strategy to abolish CB1R binding and enhance CB2R selectivity.
• Pharmacological profiling of synthesized ligands for receptor binding and signaling bias.
• Assessment of drug-like properties (BBB permeability, metabolic stability).
• In vitro evaluation of neuroprotection in primary neuronal and SH-SY5Y cell models.

Main Results:

• A novel series of selective CB2R agonists with potent anti-inflammatory and neuroprotective properties was synthesized.
• Ligands demonstrated functional bias toward specific signaling pathways.
• Compounds exhibited favorable drug-like properties, including high BBB permeability.
• Effective mitigation of oxidative stress and apoptosis, preservation of neurite complexity in disease models.

Conclusions:

• Conformational restriction is an effective strategy for developing selective CB2R agonists.
• These novel compounds show promise as efficacious agents for neurodegenerative disorders.
• The developed ligands offer neuroprotection without CB1R-mediated psychoactive effects.